Orien

Abstract

Click to increase image sizeClick to decrease image size Additional informationNotes on contributorsMichael A. CaligiuriMichael Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio. William Dalton, PhD, MD, is CEO of M2Gen, Tampa, Fla. Lorna Rodriguez, MD, PhD, is director of the Precision Medicine Initiative at the Rutgers Cancer Institute of New Jersey, New Brunswick, N.J. Thomas Sellers, PhD, MPH, is executive vice president and director of the Moffitt Cancer Center, Tampa, Fla. Cheryl Willman, MD, is director and CEO of the University of New Mexico Cancer Center, Albuquerque, N.M.William S. DaltonMichael Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio. William Dalton, PhD, MD, is CEO of M2Gen, Tampa, Fla. Lorna Rodriguez, MD, PhD, is director of the Precision Medicine Initiative at the Rutgers Cancer Institute of New Jersey, New Brunswick, N.J. Thomas Sellers, PhD, MPH, is executive vice president and director of the Moffitt Cancer Center, Tampa, Fla. Cheryl Willman, MD, is director and CEO of the University of New Mexico Cancer Center, Albuquerque, N.M.Lorna RodriguezMichael Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio. William Dalton, PhD, MD, is CEO of M2Gen, Tampa, Fla. Lorna Rodriguez, MD, PhD, is director of the Precision Medicine Initiative at the Rutgers Cancer Institute of New Jersey, New Brunswick, N.J. Thomas Sellers, PhD, MPH, is executive vice president and director of the Moffitt Cancer Center, Tampa, Fla. Cheryl Willman, MD, is director and CEO of the University of New Mexico Cancer Center, Albuquerque, N.M.Thomas SellersMichael Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio. William Dalton, PhD, MD, is CEO of M2Gen, Tampa, Fla. Lorna Rodriguez, MD, PhD, is director of the Precision Medicine Initiative at the Rutgers Cancer Institute of New Jersey, New Brunswick, N.J. Thomas Sellers, PhD, MPH, is executive vice president and director of the Moffitt Cancer Center, Tampa, Fla. Cheryl Willman, MD, is director and CEO of the University of New Mexico Cancer Center, Albuquerque, N.M.Cheryl L. WillmanMichael Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio. William Dalton, PhD, MD, is CEO of M2Gen, Tampa, Fla. Lorna Rodriguez, MD, PhD, is director of the Precision Medicine Initiative at the Rutgers Cancer Institute of New Jersey, New Brunswick, N.J. Thomas Sellers, PhD, MPH, is executive vice president and director of the Moffitt Cancer Center, Tampa, Fla. Cheryl Willman, MD, is director and CEO of the University of New Mexico Cancer Center, Albuquerque, N.M.